SOURCE: BioMedReports

BioMedReports

November 18, 2009 06:48 ET

Is Power3 Medical (OTCBB: PWRM) the Next "Vermillion Dollar Baby?"

LOS ANGELES, CA--(Marketwire - November 18, 2009) - BioMedReports.com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a special report on Power3 Medical Products (OTCBB: PWRM), the developer of several blood tests designed for early detection, monitoring and targeting of diseases like Alzheimer's, Parkinson's and breast cancer.

With 10 years of development of their technology and intellectual property, and with commercialization in sight, Power3 is at a critical point in the company's growth. Company CEO, Helen Park told BioMedReports on Tuesday afternoon:

"Power3 Medical Products has recently completed the Phase I Clinical Trials for Alzheimer's and Parkinson's diseases blood diagnostic tests with better than expected results and launched the Phase II clinical trials for both of these diseases. Our Chief Scientific Officer, Dr. Ira Goldknopf, is reporting new information on these results at the BIT meeting in China this week."

The medical community's interest in these new tests, huge market potential, pending positive news, partnerships and technical analysis here look very solid and the stock will open on Wednesday roughly three cents away from potential break-out over a previous level of resistance and previous high.

The complete report is available now at BioMedReports.com:

http://biomedreports.com/component/content/article/56-top-leading-news/18487-ready-to-run-power3-medical-products-otcpwrm.html

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

http://biomedreports.com/fda-calendar/fda-calendar.html

About BioMedReports.com

BioMedReports.com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies.

For more biomedical sector and investment news go to http://BioMedReports.com

Contact Information

  • Media Contact:
    M. Davila
    Assistant Editor
    BioMedReports.com
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556